Study Detail: Lucentis and Psychological morbidity in Retinal Vein Occlusion
Trial Description Summary : To study the psychological impact of vein occlusions. There will be two groups. One group of patients, with active disease, will be treated with Lucentis for 6 months and answer questionnaires. The second group, with inactive disease, will just complete questionniares.
Basic Trial Information
Phase: III
Disease:Vein Occlusion (either central retinal or branch)
Sponsor: Genentech
Protocol Number: FVF4638s
Status: Enrolling
Study Duration: 6 months
Eligibility Criteria:
Inclusion Criteria
CRVO in all 4 quadrants with dilated veins OR BRVO on clinical exam
BCVA 20/40-20/8,000 inclusive
OCT greater than, or equal to, 250 microns
No previous treatment that might compromise or confound assessment of the study outcomes
Exclusion Criteria
History of any laser in study eye
History of vitreal surgery
Previous treatment (either eye) with
triamcinolone
bevacizumab
pegaptabnib
ranibizumab
CVA less that 1 year before study enrollment
The above inclusion/exclusion criteria is not complete and the study coordinator will do a complete screening.
Study Title : Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion
Trial Contact Information
Site: Beachwood
Study Coordinator: Dianne H 216/831-5704 extension 253


